May 18, 2021 News by Diana Campelo Delgado Perceptions of Medication Can Predict MS Treatment Adherence, Persistence Perceptions of a medication can predict treatment adherence and persistence — sticking with the same therapy — in people with multiple sclerosis (MS), a prospective observational study found. The findings were the result of a clinical study (NCT02488343) evaluating the profile of adherence to therapy in patients ages…
May 4, 2021 News by Diana Campelo Delgado Restless Legs Syndrome More Common With Greater Disability, Spinal Lesions Restless legs syndrome, the name given to the considerable discomfort people feel in their lower limbs, accompanied by an irresistible urge to move them, more frequently affects multiple sclerosis (MS) patients than the general public, and significantly impacts sleep quality, a case control study shows. While the type of MS treatment used…
April 14, 2021 News by Diana Campelo Delgado MS Trust Invites Youth Touched by Disease to Join as ‘MSTV Reporters’ The MS Trust welcomes adolescents with a connection to multiple sclerosis (MS) to join as reporters for its YouTube channel, the U.K. charity announced. Since its April 2018 launch, MSTV has featured young people with MS or those close to them sharing their experiences and first-hand knowledge through…
March 25, 2021 News by Diana Campelo Delgado Dosing Begins in Trial of Anokion’s ANK-700 for RRMS A Phase 1 clinical trial investigating ANK-700 as a means to restore immune tolerance to myelin in people multiple sclerosis (MS) has begun dosing participants. Currently recruiting at a single site in Tennessee, the trial (NCT04602390) is expected to enroll up to 40 patients with relapsing-remitting…
March 24, 2021 News by Diana Campelo Delgado UK ‘Mega-trial’ Testing Multiple MS Therapies to Start This Year Doctors in the U.K. are planning a “mega-trial” to investigate several marketed therapies — at the same time — as potential treatments to halt the progression, or even reverse the disabilities, of multiple sclerosis (MS). The world-first Octopus trial, named for its various arms, will enable researchers to concurrently…
March 17, 2021 News by Diana Campelo Delgado ThermApparel Marks 4th Anniversary of Cooling Vest ThermApparel is observing Multiple Sclerosis Awareness Month by celebrating the fourth anniversary of its cooling vest, designed for multiple sclerosis (MS) patients and others with extreme sensitivity to heat. “Our mission was to provide customers with a state-of-the-art cooling vest that looks and feels great, and is extremely fashionable,” Kurtis…
February 25, 2021 News by Diana Campelo Delgado MS in Harmony is First Digital Music Therapy for MS Patients Bristol Myers Squibb (BMS) and the American Music Therapy Association (AMTA) are partnering with singer and actor Ben Platt, and dancer, choreographer and actor Courtney Platt, to launch MS in Harmony, the first digital music therapy for patients with multiple sclerosis (MS). “We’re thrilled to have the chance…
February 23, 2021 News by Diana Campelo Delgado MS Society in UK Commits to Raising $5.2M for Research The MS Society in the U.K. is hoping to raise £3.7 million ($5.2 million) to fund research aimed at developing new treatments for multiple sclerosis (MS). The funds will support research at the Society’s Centers of Excellence in Edinburgh and Cambridge over five years. “Our top priority…
February 23, 2021 News by Diana Campelo Delgado Johns Hopkins Neuroscientist Wins 2020 Barancik Prize for Innovation The 2020 Barancik Prize for Innovation in MS Research has been awarded to neuroscientist Dwight E. Bergles, PhD, a Johns Hopkins University professor, for his work in understanding the function of brain cells in multiple sclerosis (MS). This international prize awards $100,000 to the recipient. Administered by the National MS…
February 12, 2021 News by Diana Campelo Delgado Early-life Trauma Affects MS Development, Treatment in Mice Childhood trauma can affect disease progression of multiple sclerosis (MS) and treatment in adulthood, a study in mice suggests. The study shows that mice that experienced early-life trauma were more likely to develop an autoimmune condition and less likely to respond to common treatment with interferon beta. The study,…
February 4, 2021 News by Diana Campelo Delgado Telemedicine Found Effective During Italy’s COVID-19 Lockdown Telemedicine is a feasible and effective method of remote care for multiple sclerosis (MS) patients during the COVID-19 pandemic, an Italian study suggests. The study, “Telemedicine during the Coronavirus Disease (COVID-19) Pandemic: A Multiple Sclerosis (MS) Outpatients Service Perspective,” was published in the journal Neurology International.
January 12, 2021 News by Diana Campelo Delgado Lemtrada May Slow MS Disease Progression, Long-term Study Suggests Lemtrada (alemtuzumab) may slow the progression of multiple sclerosis (MS) and lower the conversion rate of relapsing-remitting MS (RRMS) to secondary progressive MS (SPMS), a long-term study suggests. The results showed that patients converting to SPMS — in which a person’s disability gets steadily worse — were older,…
January 7, 2021 News by Diana Campelo Delgado CXCL13, Inflammatory Marker, May Be Good at Predicting Likely MS Activity CXCL13, an inflammatory biomarker, may be a good marker of likely future disease activity in people with multiple sclerosis (MS), a study suggests. The study, “Intrathecally produced CXCL13: A predictive biomarker in multiple sclerosis,” was published in the Multiple Sclerosis Journal – Experimental, Translational and Clinical. Clinicians caring…
December 31, 2020 News by Diana Campelo Delgado MS Risk May Be Higher for Children of Diabetic Mothers, Study Suggests Children of diabetic mothers may be at more risk of developing multiple sclerosis (MS), a Danish national study suggests. The study, “Maternal diabetes and risk of multiple sclerosis in the offspring: A Danish nationwide register-based cohort study,” was published in the Multiple Sclerosis Journal. Previous studies have suggested a…
December 18, 2020 News by Diana Campelo Delgado Primary Headaches Prevalent in MS, Research Reveals The prevalence of primary headaches — those with no clear cause — is high among patients with multiple sclerosis (MS), a new study suggests. Clinical screening of headache among MS patients could help tailor individualized treatments and ease the impact of the disease for these patients. The study, “…
December 14, 2020 News by Diana Campelo Delgado Sanofi Enrolling for 2 GEMINI Trials Testing Tolebrutinib vs. Aubagio for Relapsing MS Two global Phase 3 clinical trials, both comparing Sanofi Genzyme’s investigational tolebrutinib with its approved therapy Aubagio, are enrolling a total of 1,800 people with relapsing multiple sclerosis (MS), the company said. All patients in both studies — dubbed GEMINI 1 and GEMINI 2 — will…
December 10, 2020 News by Diana Campelo Delgado Stem Cell Transplant Reduces Relapses and Disability in RRMS, Study Suggests Autologous hematopoietic stem cell transplant (AHSCT) induces a reduction in relapse rate and physical disability in patients with relapsing-remitting multiple sclerosis (RRMS) who respond inadequately to other treatments, a small study suggests. The study, “Selective cognitive dysfunction and physical disability improvement after autologous hematopoietic stem cell transplantation…
December 9, 2020 News by Diana Campelo Delgado MS Has Greater Impact on Women’s Physical Activity, Study Reveals Multiple sclerosis (MS) has a greater impact on women, reducing their levels of physical activity and increasing sedentary behavior, a recent study has found. The study, “Does Multiple Sclerosis Differently Impact Physical Activity in Women and Man? A Quantitative Study Based on Wearable Accelerometers” was published in the…
October 30, 2020 News by Diana Campelo Delgado Better Repair of Nerve Insulation May Lead to New MS Treatments There may be a better way of repairing the insulation surrounding damaged neurons that could lead to new treatments for multiple sclerosis (MS), a study suggests. The data showed that blocking the protein sphingomyelin hydrolase neutral sphingomyelinase 2, or nSMase2, could improve the quality of the myelin surrounding…
October 28, 2020 News by Diana Campelo Delgado No Association Between Skin Condition Vitiligo and MS, Study Asserts There is no significant association between multiple sclerosis (MS) and vitiligo, a skin condition in which patches of skin lose their color, a review study has found. The study, “Association of multiple sclerosis with vitiligo: a systematic review and meta-analysis,” was published in the journal…
October 26, 2020 News by Diana Campelo Delgado Variants in Key Gene Interact With Insults Like EBV to Cause MS, Study Suggests The HLA-DR15 haplotype — a set of gene variants that tend to be inherited together — in the HLA-DRB1 gene plays a role in autoimmune response and, in combination with environmental factors, contributes to the development of multiple sclerosis (MS), a study suggests. The study, “…
October 21, 2020 News by Diana Campelo Delgado NanoStilbene Better Than Copaxone at Reducing MS Symptoms in Mouse Model The nutritional supplement NanoStilbene, developed by Therapeutic Solutions International, worked better to reduce neurological damage and disease symptoms in an animal model of multiple sclerosis (MS) than the market-leading MS therapy Copaxone, the company announced. NanoStilbene is composed of easily absorbed nano-particles of pterostilbene, a…
October 20, 2020 News by Diana Campelo Delgado Aslan Pharmaceuticals to Develop Aslan003 for Autoimmune Conditions Aslan Pharmaceuticals announced it will develop Aslan003, a potent and highly selective next-generation modulator of the immune system, as a potential therapy for autoimmune diseases such as multiple sclerosis (MS). Aslan003 is a small molecule blocking the human enzyme dihydroorotate dehydrogenase (DHODH). This enzyme is believed to reduce…